MarketBeat is an American financial media company headquartered in Sioux Falls, South Dakota, founded in 2011 by Matthew Paulson as Analyst Ratings Network before rebranding in 2015. The company operates an online platform that delivers real-time financial data, market analysis, and news, aiming to empower individual investors with tools to make informed trading decisions.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu
Erdene Resource Development (TSE:ERD) reported higher second-quarter gold production and lower unit costs as the Bayan Khundii Gold Mine in southwestern Mongolia continued its ramp-up toward steadier operations.
The Bayan Khundii mine, held through the 50/50 Erdene Mongol joint venture with Mongoli
Taiwan Semiconductor insiders are ramping up open-market share purchases as strong Q2 guidance, 2nm demand, and AI-driven analyst upgrades support a bullish outlook for TSM stock.
HIVE Digital Technologies (NASDAQ:HIVE) reported fiscal first-quarter 2027 revenue of $79.1 million, up 73% from $45.6 million a year earlier and 10% sequentially, as the company expanded its Bitcoin mining operations and continued building its high-performance computing, or HPC, and artificial inte
With CrowdStrike shares trading above analyst targets, DataDog, Qualys, and Guidewire offer AI cybersecurity exposure with strong earnings, guidance increases, and analyst support.
U-Haul, Avis Budget, Public Storage, Extra Space Storage and CubeSmart offer exposure to migration trends, with varying growth, dividend yields and analyst price targets.
argenx (NASDAQ:ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM.
The study evaluated e
Cosan (NYSE:CSAN) reported a narrower net loss for the second quarter of 2026 as the Brazilian conglomerate advanced debt-reduction, divestment and cost-cutting efforts designed to simplify its holding-company structure.
Net loss totaled BRL 320 million for the quarter, an improvement from the prio
PagSeguro Digital (NYSE:PAGS) reported second-quarter results marked by continued growth in banking engagement, credit balances and deposits, while management said it maintained its full-year targets despite a more challenging macroeconomic environment and elevated interest rates in Brazil.
Total p
Syntec Optics (NASDAQ:OPTX) reported record second-quarter revenue for 2026, returning to operating and net profitability as sales increased across its medical, defense, consumer and communications markets.
Revenue for the quarter totaled approximately $8.3 million, up 26% from approximately $6.6 m
Freightos (NASDAQ:CRGO) reported second-quarter 2026 revenue of $7.7 million, up 3% from a year earlier and above the company’s expectations, as growth in platform revenue offset a decline in solutions revenue. The company also said its adjusted EBITDA loss narrowed to $2 million, its lowest reporte
DeFi Development (NASDAQ:DFDV) used its second-quarter 2026 earnings update call to emphasize its strategy of building long-term Solana per-share exposure through validator operations, on-chain deployment and leverage, while simplifying its capital structure and reducing noncore complexity.
Chief E
BlackRock, DLocal, Chevron, Williams Companies, and MetLife pay solid dividends and carry favorable analyst ratings, offering income investors growth exposure and price target upside.
Quantum Computing Inc. and Infleqtion posted strong revenue growth but widening losses in Q2 earnings, leaving IonQ ahead of smaller rivals and D-Wave as quantum stocks diverge.
Mobileye, Ondas Holdings and Palladyne AI have each fallen under $10, but for different reasons, ranging from leadership uncertainty to dilution concerns to thin analyst coverage.
H World Group (NASDAQ:HTHT) reported second-quarter revenue growth and higher profitability, supported by expansion in China, improving room rates and continued growth in its managed and franchised hotel business.
Group revenue rose 10.8% year over year to RMB7.1 billion in the second quarter, Chie
Fulcrum Therapeutics (NASDAQ:FULC) has entered into an all-stock merger agreement with privately held Slate Medicines, a migraine-focused biotechnology company, in a transaction expected to close in the fourth quarter of 2026, subject to stockholder approval and customary closing conditions.
Alex S
BitFuFu (NASDAQ:FUFU) reported second-quarter 2026 results marked by lower cloud-mining revenue and a net loss amid weaker Bitcoin prices, while management emphasized growth in self-mining production, expansion of hosting services and investments in more efficient equipment.
Chairman and CEO Leo Lu
Buffered ETFs PJUL, BSEP, and QBUF offer investors varying levels of downside protection and capped upside tied to the S&P 500 or Nasdaq-100, using options-based strategies.
JFrog's strong Q2 results and raised guidance sparked widespread analyst price target increases, with technical trends and cloud growth pointing to potential new highs for FROG stock.
Sandisk (NASDAQ:SNDK) used its investor event to outline a strategy centered on NAND technology scaling, longer-term customer agreements, AI data-center demand and shareholder cash returns.
Chairman and Chief Executive Officer David Goeckeler said the company has spent the past 18 months strengthen
Solid Power (NASDAQ:SLDP) said it is advancing a capital-light strategy centered on supplying sulfide solid electrolyte materials for all-solid-state batteries, while targeting increased production capacity, deeper partnerships and expansion into markets beyond electric vehicles.
During a JPMorgan
Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis, company executive
SailPoint (NASDAQ:SAIL) outlined how identity governance and administration systems could help government organizations manage machinery-of-government changes, or MOGs, which the company described as the public-sector equivalent of corporate reorganizations.
In the first of a four-part government-f
Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat.
Smith sai
Recursion Pharmaceuticals (NASDAQ:RXRX) is using artificial intelligence to generate and analyze biological data in an effort to improve drug discovery, advance internal therapeutic programs and support collaborations with larger pharmaceutical companies, CFO and President of Recursion U.K. Ben Tayl
Rumble (NASDAQ:RUM) is positioning its recently combined operations as an AI compute infrastructure business with a substantial 2027 power pipeline, while continuing to operate its established video platform separately.
Speaking at an event with Canaccord Genuity Equity Research Senior Analyst King
Repay (NASDAQ:RPAY) executives said the company is positioning itself as a broader provider of consumer bill payment, bill presentment and communications services following its acquisition of KUBRA, while targeting an acceleration in organic growth and using cash flow to reduce leverage.
Speaking a
Roper Technologies (NASDAQ:ROP) is pursuing a strategy centered on long-term free-cash-flow-per-share growth, portfolio collaboration and acquisitions of vertical-market software businesses, while increasingly deploying artificial intelligence across its operations and products, Chief Financial Offi
RenovoRx (NASDAQ:RNXT) executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTradin
Real Brokerage (NASDAQ:REAX) Founder and CEO Tamir Poleg said the company had grown to more than 36,000 agents across the U.S. and Canada, positioning its technology-driven brokerage model for further expansion as it pursues its acquisition of RE/MAX Holdings.
Speaking at an Oppenheimer event, Pole
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
Presid
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
Vance, who has been CEO for about 10 months after previously serving
Rani Therapeutics (NASDAQ:RANI) outlined its strategy to expand the use of its RaniPill oral biologic-delivery platform through a mix of technology partnerships, selectively licensed product programs and investments in manufacturing capacity.
Chief Executive Officer Talat Imran described the clinic
QuickLogic (NASDAQ:QUIK) is targeting aerospace, defense and other long-life infrastructure applications as it expands its programmable logic offerings, President and CEO Brian Faith said during a Canaccord Genuity discussion.
Faith described programmable logic as a semiconductor segment experienci
Quanterix (NASDAQ:QTRX) CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma marke
Qualys (NASDAQ:QLYS) executives said the company’s second-quarter performance reflected growing customer demand for vulnerability remediation, patch management and Enterprise TruRisk Management, or ETM, while positioning newer products as potential drivers of longer-term growth.
During an investor
The Metals Company faces a licensing delay to October, but analysts remain optimistic as revenue could begin in late 2027 amid growing US national security interest in deep-sea mining.
Palvella Therapeutics (NASDAQ:PVLA) is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
OneSpaWorld posted record Q2 revenue and adjusted earnings, raised full-year guidance, and retains an analyst Buy rating, though it remains heavily dependent on the cruise industry.
PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.
Meta Platforms and Tesla show improving RSI readings after recent selloffs, with both Magnificent Seven stocks facing earnings volatility but analysts still forecasting double-digit upside ahead.
People Incorporated Common Stock (NASDAQ:PPLI) is focusing its capital allocation on its MGM minority stake and its People media business while seeking new homes for several non-core assets, Chief Financial Officer Tim Quinn said during a fireside chat.
Quinn said the former IAC has identified MGM
Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Co
Affiliated Managers Group posted record Q2 revenue, earnings, and assets under management, driven by an alternatives push, though shares trading near consensus price targets suggest limited further upside.
Pagaya Technologies (NASDAQ:PGY) CFO Jonathan Dobres outlined the company’s growth strategy, funding model and profitability trajectory at the 46th Annual Canaccord Growth Conference, emphasizing expansion with existing lending partners as well as new partner additions.
Dobres described Pagaya as a
Microsoft plans to unveil its Maia 300 AI chip in September, seeking TSMC capacity for over 300,000 units by 2027 as it aims to reduce reliance on NVIDIA processors.
HGER, MCHI, and VFLO have posted strong summer returns by targeting commodities, Chinese equities, and free-cash-flow-rich growth stocks, respectively, amid inflation and rate uncertainty.
Progyny (NASDAQ:PGNY) CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management’s confidence in its outlook for the remainder of the year.
Spea
Perion Network (NASDAQ:PERI) is positioning its Perion One platform as an AI-enabled layer designed to help advertisers manage campaigns across a fragmented digital advertising market, Chief Executive Officer Tal Jacobson said during a Canaccord Genuity discussion.
Jacobson said advertisers are see
Pegasystems (NASDAQ:PEGA) COO and CFO Ken Stillwell said the company is positioning its platform around enterprise workflows that require consistent, governed and predictable outcomes, particularly in regulated or control-heavy environments.
Speaking at Oppenheimer’s 29th Annual Technology Conferen
Pegasystems (NASDAQ:PEGA) CFO Ken Stillwell outlined the company’s position as a workflow platform for large enterprises, its expanding AI product capabilities and its plans to improve sales execution following a softer first half for annual contract value growth.
Speaking at a Canaccord fireside c
Pacific Biosciences of California (NASDAQ:PACB) reported second-quarter revenue of $39 million, including $20 million in consumables revenue, $13 million in instrument revenue and $6 million in services revenue, CFO Jim Gibson said during the Canaccord Genuity Growth Conference.
Revenue increased s
Ouster (NASDAQ:OUST) executives said the company expects its recently launched Rev8 lidar platform to become the core of its sensing business over the next several years, supported by early multimillion-dollar orders and a broader push into software, cameras and sensor fusion.
Speaking at an Oppenh
onsemi (NASDAQ:ON) executives said the company is increasing factory utilization to meet stronger demand in AI data center markets while maintaining its longer-term focus on automotive and industrial customers.
Speaking at a KeyBanc Capital Markets event, President and CEO Hassane El-Khoury said th
Universal Display (NASDAQ:OLED) President and CEO Steve Abramson said the OLED industry’s continued investment in new manufacturing capacity reflects panel makers’ confidence in long-term adoption, even as smartphone demand faces near-term pressure from higher component and memory costs.
Speaking a
Orthofix Medical (NASDAQ:OFIX) executives said the company’s updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among s
Ocugen (NASDAQ:OCGN) is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar
NXP Semiconductors (NASDAQ:NXPI) sees a meaningfully improved business environment compared with 90 days ago and a year ago, with book-to-bill ratios solidly above one across its end markets, according to Senior Vice President of Investor Relations Jeff Palmer.
Speaking at a KeyBanc Capital Markets
Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record Signatera volumes, continued revenue and average selling price strength, improved gross margins and narrow
Insight Enterprises (NASDAQ:NSIT) is targeting growth in artificial intelligence infrastructure and AI services while seeking to improve operating efficiency under its newly introduced three-year “One Insight” plan, CEO Jack Azagury said during a discussion hosted by Canaccord.
Azagury, who joined
Terra Innovatum Global S.R.L. (NASDAQ:NKLR) said it is advancing licensing and construction preparations for its SOLO nuclear microreactor, with the company targeting a first-of-a-kind deployment in Illinois by late 2027 and commercial operations in 2028.
Speaking at Canaccord Genuity’s 46th Annual
Nexxen International (NASDAQ:NEXN) outlined its commercial priorities following a series of executive appointments, highlighting its end-to-end advertising technology platform, connected TV growth, enterprise customer expansion and investments in artificial intelligence.
Chance Johnson, who was new
NioCorp Developments (NASDAQ:NB) detailed its recently published 2026 technical report for the Elk Creek Critical Minerals Project in Nebraska, outlining an expanded product suite, updated mine design and projected economics for the proposed underground mining and processing operation.
Mark Smith,
Nature's Sunshine Products (NASDAQ:NATR) outlined a strategy to double sales to $1 billion and expand EBITDA margins to 15%, with Chief Executive Officer Ken Romanzi pointing to geographic expansion, digital and retail channel development, marketing initiatives and acquisitions as the company’s prim
Truist Securities upgraded Best Buy to Buy with a $95 price target, citing rising sales of AI-enabled gadgets ahead of the retailer's earnings report due later this month.
Everspin Tech (NASDAQ:MRAM) outlined plans to expand its MRAM memory product portfolio, manufacturing footprint and revenue base during an Oppenheimer presentation, with management targeting more than $100 million in annual revenue by fiscal 2029.
President and CEO Sanjeev Aggarwal said Everspin de
Applied Materials beat Q3 estimates and raised guidance, but shares fell 6% as sequential growth slowed and gross margin guidance stalled at 50.4% for Q4.
Intuitive Machines missed Q2 revenue and EPS estimates, but its $1.8 billion backlog, analyst Buy ratings, and institutional buying point to a path toward profitability.
Monro Muffler Brake (NASDAQ:MNRO) shareholders elected eight directors, approved an advisory vote on named executive officer compensation and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm at the company’s 2026 annual meeting.
The virtual meeting
Texas Roadhouse and Brinker International shares have rallied on easing beef costs, stronger comps, and improved margin trends, with Brinker also raising its fiscal 2027 guidance.
Merit Medical Systems (NASDAQ:MMSI) is focused on completing the objectives of its current long-range plan while developing its next strategic framework, Chief Financial Officer and Treasurer Raul Parra said during a Canaccord investor event.
Parra said the company remains “hyper-focused” on execut
AirJoule Technologies faces record short interest amid cash burn concerns, but rising Kubota deployments, UL certification progress, and analyst Buy ratings suggest a possible short squeeze ahead.
